This site is intended for
U.S.
Healthcare Professionals only.

For Patients

At the Forefront of
Immuno-Oncology Research

CTLA-4

See how CTLA-4 signaling limits long-term immunity

Read more

Clinical Endpoints

Learn how I-O requires a more comprehensive approach to the assessment of clinical endpoints

Learn more

Memory T Cells

Learn how memory T cells may provide long-term immunity

Read more

PD-L1

See how our research is exploring the role of PD-L1 as an I-O biomarker

Learn more

Immune Pathways Combination

Learn how signaling pathways combine to maintain immune balance

Read more

LAG-3

See how LAG-3 inhibits immune responses

Read more

PD-1

See how PD-1 promotes T-cell exhaustion and a diminished antitumor response

Learn more

Exploring the potential of the immune system
to fight cancer

Immune
Pathways

Immune pathways under investigation may inform strategies for restoring antitumor immunity

Read more

I-O
Biomarkers

Immuno-Oncology
(I-O) biomarkers may be used to advance precision medicine

Learn more

Clinical
Expectations

I-O has unique considerations and distinct characteristics that continue to be researched

Read more

Potential of
I-O Research

Tumor immunogenicity across a broad range of tumors supports the need for ongoing I-O research

Learn more

Resources for You & Your Patients

Find up-to-date
educational tools

Clinical Trials

Learn more about
our current clinical trials

2:37

Thumbnail for the I-O Biomarkers: Under Investigation for Their Role in Immuno-Therapy video

Thumbnail for the I-O Biomarkers: Under Investigation for Their Role in Immuno-Therapy video

I-O biomarkers: Under investigation for their role in immuno-therapy

Learn more about where our I-O biomarker research is focused

Watch video